派安普利单抗联合化疗在进展期胃癌患者中的应用  

Application of penpulimab combined with chemotherapy in patients with advanced gastric cancer

作　　者：杨琳娜[1] 高原 王娟[1] YANG Linna;GAO Yuan;WANG Juan(Department of Gastroenterology,the Affiliated Hospital of Xinyang Vocational and Technical College,Xinyang 464000,He’nan,China;Department of Oncology,the Affiliated Hospital of Xinyang Vocational and Technical College,Xinyang 464000,He’nan,China)

机构地区：[1]信阳职业技术学院附属医院消化内科,河南信阳464000 [2]信阳职业技术学院附属医院肿瘤科,河南信阳464000

出　　处：《癌症进展》2025年第2期160-162,166,共4页Oncology Progress

摘　　要：目的探讨派安普利单抗联合化疗在进展期胃癌患者中的应用效果。方法将82例进展期胃癌患者按照治疗方法的不同分为对照组(42例,采取化疗)和观察组(40例,采取派安普利单抗联合化疗)。比较两组患者的治疗效果、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、不良反应发生情况及N分期降期率。结果观察组患者客观缓解率和N分期降期率均明显高于对照组,差异均有统计学意义(P﹤0.01)。治疗后,两组患者CEA、CA19-9水平均较治疗前降低,且观察组患者CEA、CA19-9水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论派安普利单抗联合化疗治疗进展期胃癌临床疗效较好,且可降低血清肿瘤标志物水平,提高N分期降期率,值得推广使用。Objective To investigate the efficacy of penpulimab combined with chemotherapy in patients with advanced gastric cancer.Method A total of 82 patients with advanced gastric cancer were divided into control group(42 cases,chemotherapy)and observation group(40 cases,penpulimab combined with chemotherapy)according to different treatment methods.The therapeutic effect,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)]levels,incidence of adverse reactions and N stage decline rate were compared between the two groups.Result The objective response rate and N stage decline rate in observation group were significantly higher than those in control group,the differences were statistically significant(P<0.01).After treatment,the levels of CEA and CA19-9 in two groups were lower than those before treatment,and the levels of CEA and CA19-9 in observation group were lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Penpulimab combined with chemotherapy has good clinical efficacy in the treatment of advanced gastric cancer,and can reduce the levels of serum tumor markers and increase the N stage decline rate,which is worthy of popularization.

关 键 词：派安普利单抗 化疗 进展期胃癌 血清肿瘤标志物 N分期降期率 

分 类 号：R735.2[医药卫生—肿瘤]